Pleasanton, CA, USA
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of Bina Technologies, Inc. (Bina), a privately held company based in Redwood City, California, USA. Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data. Bina’s proprietary on-market Genomic Management Solution, Bina-GMS(1), empowers basic, translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data.
“The acquisition of Bina is a significant step for Roche to enable the promise of personalized healthcare by delivering the highest quality genomic data possible,” said Dan Zabrowski, Head of Roche Sequencing. “Informatics and data management are critical to providing a seamless, end-to-end sequencing solution. Bina’s products are designed to improve the efficiency and value of genomic analysis, and the company continues to develop new methodologies and algorithms that link NGS data to disease-relevant genetic markers.”
“Roche’s acquisition of Bina is a great validation of our work and technology. It is also an indication of how informatics and data science are going to play a major role in the future of medicine,” said Narges Bani Asadi, Founder and CEO of Bina. “We found great alignment between our company's vision and values, and we are very excited about the possibilities of working with Roche’s global team and serving academic, translational and clinical research markets together in the future.”
The acquisition by Roche will enable Bina to accelerate product development and global commercialization of the Bina-GMS as an enterprise software system supporting multiple sequencing technologies while developing a solution for Roche sequencing systems. Roche will also continue to grow Bina's unique interdisciplinary team of bioinformatics scientists, computer scientists and software engineers.
Bina will be integrated into Roche Sequencing Unit in Q1 2015 and will continue to focus on expanding its innovative genomic analysis solutions portfolio.
1.Bina products are For Research Use Only. Not for use in diagnostic procedures.
About Bina Technologies
Bina Technologies builds next-generation technologies for scalable and accurate processing and management of genomic information. Bina’s Genomic Management Solution is an integrated, scalable, and comprehensive analysis platform that empowers clinical and translational researchers to gain insight from their genomic data sets. Bina’s Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalized medicine. Learn more about Bina’s product, technologies, and team at www.bina.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.